Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. by Boufassa, Faroudy et al.
Immune deficiency could be an early risk factor for
altered insulin sensitivity in antiretroviral-naive
HIV-1-infected patients: the ANRS COPANA cohort.
Faroudy Boufassa, Ce´cile Goujard, Jean-Paul Viard, Robert Carlier,
Be´ne´dicte Lefebvre, Patrick Yeni, Olivier Bouchaud, Jacqueline Capeau,
Laurence Meyer, Corinne Vigouroux
To cite this version:
Faroudy Boufassa, Ce´cile Goujard, Jean-Paul Viard, Robert Carlier, Be´ne´dicte Lefebvre, et al..
Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-
naive HIV-1-infected patients: the ANRS COPANA cohort.. Antiviral Therapy, International
Medical Press, 2012, 17 (1), pp.91-100. <10.3851/IMP1916>. <inserm-00848065>
HAL Id: inserm-00848065
http://www.hal.inserm.fr/inserm-00848065
Submitted on 25 Jul 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Immune deficiency could be an early risk factor for altered insulin 
sensitivity in antiretroviral-naïve HIV-1-infected patients: the ANRS 
COPANA cohort 
 
Running head:  
Immune deficiency and insulin resistance in untreated HIV infection 
 
F. Boufassa,1 C. Goujard,1,2 JP. Viard,3 R. Carlier,4 B. Lefebvre,5 P. Yeni,6 O. 
Bouchaud,7 J. Capeau,8,9,10 L. Meyer,1 and C. Vigouroux,8,9,10 for the ANRS COPANA 
Cohort Study Group* 
 
1 Equipe "VIH et IST", Centre de Recherche en Epidémiologie et Santé des 
Populations (CESP), INSERM U1018; Univ Paris-Sud 11, Faculté de Médecine; 
Service d’Epidémiologie et de Santé Publique, Hôpital Bicêtre, AP-HP, Le Kremlin 
Bicêtre, France 
2 Service de Médecine Interne, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France 
3 Centre de Diagnostic et de Thérapeutique, Hôpital Hôtel Dieu, AP-HP, Paris, 
France 
4 Service de Radiologie et Imagerie Médicale, Hôpital Raymond Poincaré, AP-HP, 
Garches, France 
5 Service des Maladies Infectieuses, Hôpital Saint Antoine, AP-HP, Paris, France 
6 Service des Maladies Infectieuses, Hôpital Bichat, AP-HP, Paris, France 
7 Service des Maladies Infectieuses, Hôpital Avicenne, AP-HP, Bobigny, France 
8 INSERM, CDR Saint-Antoine, U938, Paris, France  
9 UPMC Univ Paris06, UMR_S938, Paris, France  
10 Service de Biochimie et Hormonologie, Hôpital Tenon, AP-HP, Paris, France  
* See appendix 
 
Corresponding author:  
Corinne Vigouroux, INSERM U938, Equipe Capeau, Faculté de médecine Pierre et 
Marie Curie, Site St Antoine, 27 rue Chaligny, 75012 Paris, France 
Tel +33 140 011 352; fax: + 33 140 011 432; email: corinne.vigouroux@inserm.fr 
Immune deficiency and insulin resistance in untreated HIV infection 
 2 
Abstract  
Background: The relationships between immunovirological status, inflammatory 
markers, insulin resistance and fat distribution have not been studied in recently 
diagnosed (<1 year) antiretroviral-naïve HIV-1-infected patients. 
 
Methods: We studied 214 antiretroviral-naïve patients at enrolment in the 
metabolic sub-study of the ANRS COPANA cohort. We measured clinical, 
immunovirological and inflammatory parameters, glucose/insulin during oral 
glucose tolerance test (OGTT), adipokines, subcutaneous and visceral fat surfaces 
(SAT and VAT, assessed by computed tomography) and the body fat distribution 
based on dual-energy X-ray absorptiometry (DEXA). 
 
Results: Median age was 36 years; 28% of the patients were female and 35% of 
sub-Saharan origin; 20% had low CD4 counts (!200/mm3). Patients with low CD4 
counts were older and more frequently of sub-Saharan Africa origin, had lower BMI 
but not different SAT/VAT ratio and fat distribution than other patients. They also 
had lower total, LDL- and HDL-cholesterolemia, higher triglyceridemia and post-
OGTT glycemia, higher markers of insulin resistance (insulin during OGTT and 
HOMA-IR) and of inflammation (hsCRP, IL-6, TNF", sTNFR1 and sTNFR2). After 
adjustment for age, sex, geographic origin, BMI and waist circumference, increased 
insulin resistance was not related to any inflammatory marker. In multivariate 
analysis, low CD4 count was an independent risk factor for altered insulin sensitivity 
(#-coefficient for HOMA-IR: +0.90; p=0.001; CD4>500/mm3 as the reference), in 
addition to older age (#: +0.26 for a 10-year increase; p=0.01) and higher BMI 
(#: +0.07 for a 1-kg/m2 increase; p=0.003).  
 
Conclusions: In ART-naive patients, severe immune deficiency but not 
inflammation could be an early risk factor for altered insulin sensitivity.  
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Introduction  
Highly active antiretroviral therapy (ART) has markedly improved the prognosis of 
HIV infection. In industrialized countries, where HIV infection is generally well-
controlled and routinely managed as a chronic disease, morbidity and mortality are 
increasingly unrelated to AIDS [1] and cardiovascular and metabolic complications 
represent emerging challenges in the management of HIV-infected patients [2]. 
Several studies have shown that ART is independently associated with metabolic 
and cardiovascular diseases [3-8]. However, chronic HIV infection itself also 
contributes to cardiovascular risk [9-11], with both immune deficiency and immune 
activation probably playing important roles [12, 13]. In addition, several reports 
suggested that low CD4 count during HIV infection could be independently 
associated with diabetes [3, 5, 14, 15]. Brown et al. have recently revealed that 
systemic low-grade inflammation under ART, but not before treatment initiation, 
was a risk factor for incident diabetes [16]. Interestingly, in this study, low CD4 
count before ART was also associated with incident diabetes under treatment.  
As insulin resistance is probably the first event leading to the development of 
diabetes in HIV-infected patients under ART [8, 17], we found of high 
pathophysiological interest to search for the risk factors for altered insulin 
sensitivity in HIV-infected patients before ART initiation. A few studies have 
addressed this point [18, 19], but have not assessed the possible relationships 
between inflammatory markers before ART and the risk of insulin resistance or 
diabetes.  
In this work, we used data collected from antiretroviral-naive patients, enrolled in 
the metabolic sub-study of the multicentre ANRS COPANA cohort study, to search 
for relationships between immunovirological, anthropometric, imaging, metabolic 
and inflammatory parameters. Our results show that the immune deficiency 
associated with HIV infection could be an early contributing factor to altered insulin 
sensitivity, independently of inflammatory markers and in the absence of body fat 
redistribution.  
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Patients and methods 
Patients 
The main objective of the ongoing ANRS COPANA cohort is to prospectively 
evaluate the impact of HIV infection and ART on morbidity and mortality in recently 
diagnosed (<1 year) HIV-1-infected ART-naïve adults, in France. The Paris-Cochin 
Ethics Committee approved the study protocol and all the participants gave their 
written informed consent.  
Demographic, clinical and biological data were collected at enrolment and every 
year thereafter. In 21 of the 38 participating centres, all eligible patients were also 
invited to enter a metabolic sub-study comprising a 75g oral glucose tolerance test 
(OGTT), performed after a fasting period of at least 8h, with blood sampling at T0 
and T120 min, centralized assays of inflammatory markers, insulin and adipokines, 
computed tomography (CT) at the level of the L4 vertebra and dual-energy X-ray 
absorptiometry (DEXA).  
Among the 800 patients enrolled in the COPANA cohort, 214 joined the metabolic 
sub-study and were considered for the present analyses.  
 
Methods 
Blood pressure and physical characteristics (height, weight, waist and hip 
circumferences) were measured at enrolment. The country of birth, sexual 
preference, and the personal history of AIDS-defining illnesses, cardiovascular 
disease and diabetes were recorded. T0 (fasting) and T120 min post-charge 
samples were collected during OGTT. Fasting total, HDL- and LDL-cholesterol, 
triglycerides and glucose were measured with standard procedures. CD4 and CD8 
lymphocyte counts and plasma HIV-1 RNA viral load were routinely measured, and 
the patients were tested for hepatitis B virus surface antigen and for antibodies to 
hepatitis C virus in each participating centre.  
Cryopreserved serum was used for centralized measurements at Tenon Hospital 
Biochemistry Department. Insulin was measured with a method avoiding cross-
reactivity with proinsulin (ARCHITECT system, Abbott, USA) at T0 and T120 min of 
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the OGTT. Homeostasis model assessment of insulin resistance (HOMA-IR) and 
insulin secretion (HOMA-B, reflecting pancreatic !-cell function) values were 
calculated as follows: [HOMA-IR = (T0 insulin (mU/L) x T0 glucose (mmol/L) / 
22.5] and [HOMA-B = (20 x T0 insulin) / (T0 glucose - 3.5)] [20]. Diabetic status 
was recorded on the basis of self-reported diabetes confirmed by the physician, 
regular use of anti-diabetic medication, fasting glucose " 7 mmol/L and/or T120 
glucose " 11.1 mmol/L. Impaired glucose tolerance was defined, in the absence of 
diabetes, by T120 glucose above 7.8 mmol/L [21]. The most recent definition of the 
metabolic syndrome was used [22]. High-sensitivity C-reactive protein (hsCRP) was 
determined by nephelometry on an IMMAGE analyser (Beckman-Coulter, Villepinte, 
France). Serum total adiponectin, leptin, interleukin-6 (IL-6), monocyte 
chemoattractant protein-1 (MCP-1), tumor necrosis factor alpha (TNF") and its 
soluble receptors sTNFR 1 and 2 were measured with multiplexed bead-based 
immunoassays (Linco Research Inc., St Charles, MO, USA and BioSource 
International Inc., Camarillo, CA, USA), with respective detection limits of 145.6, 
85.4, 1.6, 0.14, 0.14, 15 and 15 pg/mL, on a Bio-Plex 200 system (Bio-Rad 
laboratories Inc., Hercules, CA, USA) using Bio-Plex Manager TM 3.0 software.  
Subcutaneous and visceral adipose tissue surface areas (SAT and VAT) were 
calculated for 139 patients, in the same radiological centre, from 1-cm 
reconstructed slices of abdominal L4 CT scans, using an Extended Brilliance 
workstation and QCTA software (EBW, QCTA, Philips Medical Systems, Eindhoven, 
The Nederlands). DEXA was performed in 102 patients using Lunar Prodigy (GE 
Medical Systems, Madison, WI) or Hologic (Hologic, Inc., Bedford, MA) 
densitometers, the same device being always used for a given patient, and 
percentages of total, trunk and limb fat were recorded.  
 
Statistical analyses 
SAS software version 9.1 (SAS Institute, Cary, North Carolina) was used for all 
analyses. To investigate the impact of immune deficiency on metabolic parameters, 
the patients were categorized into four groups according to their CD4 counts at 
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enrolment: !200 (“low CD4”); 201-350; 351-500 and >500/mm3. Continuous 
variables are reported as medians and 25th to 75th percentiles (inter quartile range, 
IQR), and categorical variables as percentages. Non parametric Kruskal-Wallis tests 
were used to compare continuous variables and the chi-squared or Fisher’s test was 
used for categorical variables. All comparisons of anthropometric measurements 
were adjusted for sex by using multiple logistic or linear regression models (Tables 
1 and 2); p values were those estimated from the Wald test values. Pearson 
correlation and partial correlation coefficients were used to estimate the 
correlations between continuous variables, with and without adjustment for age, 
sex, body mass index (BMI), waist circumference, SAT, VAT and geographic origin. 
Alternative models using percentage of total fat instead of BMI, or trunk and limb 
fat instead of waist circumference, were also tested. Several multivariate linear 
regression models were also used to examine the relations between each insulin 
resistance marker (HOMA-IR, T0 and T120 insulin) as the dependent variable and 
age, sex, BMI, geographic origin, and CD4 count or HIV RNA level (CD4 count and 
HIV RNA levels could not be entered simultaneously in the model, as too few 
patients had both low CD4 count and low viral load); the p values are those 
estimated from the Wald test values by the SAS GLM. 
 
Results 
Baseline characteristics (Table 1) 
214 patients were studied less than one year after HIV diagnosis (median 4.7 
months) and before any ART. Median age at inclusion was 36 years [IQR: 31-42]; 
28% were women (n=60); 75 patients (35%) originated from sub-Saharan Africa 
and 102 (48%) from European countries. Most patients (97%) had been infected by 
the sexual route, and 51% defined themselves as heterosexual. Twenty-five 
patients (12%) presented with a previous AIDS-defining event (tuberculosis in 9 
cases) at the time of HIV diagnosis. The median CD4 count was 398/mm3 [248-
551], and 20% of the patients (n=42) had low CD4 (!200/mm3). The median HIV-1 
RNA level was 4.4 log10 copies/mL [3.8-4.9]. The prevalence of HBV and HCV 
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infection was low (4.6% and 3.8%, respectively). One patient, no longer a current 
user, reported a history of opiate use.  
Table 1 shows the patients’ characteristics according to their baseline CD4 counts. 
As expected, HIV RNA levels were significantly higher and previous AIDS-defining 
events more frequent in patients with low CD4 (!200/mm3). Lower CD4 count was 
associated with older age, female sex and sub-Saharan Africa origin (p<0.001, 
=0.05 and =0.001, respectively), tended to be associated with lower BMI and waist 
circumference (p=0.07 and 0.08, respectively), but not with HCV co-infection. 
When considering patients with CD4 !200/mm3, their BMI was significantly lower 
than that of other patients (22.0 versus 22.9 kg/m2, p adjusted for sex = 0.02). 
As expected, the fasting glucose level and the prevalence of glucose tolerance 
abnormalities (i.e. impaired glucose tolerance or diabetes) were significantly related 
to age, BMI and waist circumference (all p values <0.001). In addition, when 
considering both T0 and T120-post OGTT glucose, the prevalence of impaired 
glucose tolerance or diabetes tended to be increased, although not significantly, in 
patients with lower CD4 counts (p adjusted for sex = 0.07). 
 
Lower cholesterol and higher triglyceride levels associated with lower CD4 
counts and higher viral load 
Total, HDL- and LDL-cholesterol levels correlated positively with CD4 counts 
(r=+0.21, +0.14 and +0.24; p=0.002, =0.05 and <0.001) and negatively with the 
HIV RNA level (r=-0.21, -0.32, and -0.19; p=0.003, <0.001, and =0.007, 
respectively), these associations being maintained after adjustment for BMI. The 
reverse situation was observed for triglycerides levels that were negatively related 
to the CD4 count and positively to the viral load (r=-0.23 and +0.18, p=0.001 and 
=0.01). In addition, triglyceride levels were related to markers of insulin resistance, 
fasting insulin, and HOMA-IR (r=+0.32 and +0.30, respectively; p<0.0001). 
Otherwise triglycerides levels were related to inflammatory markers (hsCRP, MCP-
1, TNF", sTNFR1 and IL-6; respectively r=+0.17, +0.23, +0.23, +0.18 and +0.17; 
p=0.02, 0.003, 0.002, 0.02 and 0.03). Levels of triglycerides and total, LDL- and 
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HDL-cholesterol were not related to the geographic origin. The correlation between 
triglyceride and CD4 counts remained significant after adjustment for fasting 
insulin, hsCRP, MCP-1, TNF", sTNFR1 or IL-6. Therefore, cholesterol values were 
decreased in situation of immune deficiency while increased triglycerides were 
independently associated with markers of immune deficiency and of insulin 
resistance. 
 
Insulin resistance markers were negatively related to the CD4 count  
We observed no significant difference in fasting or T120 post-OGTT glycemia across 
the CD4 count subgroups (Table 2). However, when patients with CD4 counts 
!200/mm3 were compared to other patients, their T120 post-charge glycemia was 
significantly increased (median 5.3 versus 5.0 mmol/L, p adjusted for sex = 0.04). 
In addition, although patients with CD4 !200/mm3 were leaner than other patients, 
they had significantly higher insulin resistance markers: median values of T0 
insulin, 6.6 vs 5.0 mU/L (p=0.03), of T120 insulin, 33.3 vs 15.0 mU/L (p<0.001) 
and of HOMA-IR, 1.4 vs 1.0 (p=0.02). HOMA-B, a marker of insulin secretion, was 
also significantly higher in patients with low CD4 counts.  
Serum levels of leptin and adiponectin did not differ according to the CD4 count. As 
expected, leptin levels correlated positively with BMI, TAT (total adipose tissue, i.e. 
SAT plus VAT), percentage of total fat, and fasting insulin (r=+0.49, +0.27, +0.70 
and +0.17; p<0.001, =0.003, <0.001, =0.03, respectively). In addition, 
adiponectin correlated negatively with fasting insulin (r=-0.19; p=0.02) and VAT 
(r=-0.20; p=0.05) and positively with HDL-cholesterol (r=+0.18; p=0.03). 
Body fat distribution was assessed by measurements of SAT and VAT (on L4-CT 
scan), and percentage of total, tru nk and limb fat (from DEXA). Although patients 
with CD4 !200/mm3 as compared to those with >200/mm3 had lower BMI, their 
body fat segmental distribution assessed by the ratios SAT/VAT, percentage of limb 
or trunk/total fat, was not different (data not shown). 
In addition, patients of sub-Saharan Africa origin had or tended to have higher 
levels of insulin resistance markers T0 or T120 insulin, and HOMA-IR than the other 
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patients (beta coefficients: +2.1, +8.37 and +0.42 ; p=0.01, 0.02 and 0.06, 
respectively). However, geographic origin was not associated with impaired glucose 
tolerance and/or diabetes.  
After adjustment for age, sex, BMI, waist circumference and geographic origin, the 
insulin resistance markers (T0 and T120 insulin and HOMA-IR) remained negatively 
correlated with CD4 counts. Using alternative models with adjustments for 
percentage of total fat instead of BMI (or for percentage of trunk and limb fat, or 
SAT and VAT, instead of waist circumference) led to similar conclusions.  
We also considered HIV RNA levels instead of CD4 counts: after similar 
adjustments, HIV RNA levels correlated with T0 insulin (r=+0.23; p=0.009) but not 
significantly with HOMA-IR or T120 insulin (p=0.06 and 0.17, respectively). Finally, 
HCV and HBV infection were not related to insulin resistance markers. 
 
Inflammatory markers were increased in patients with low CD4 counts but 
were not related to altered insulin sensitivity  
IL-6, TNF", sTNFR1, sTNFR2 (Table 3) and hsCRP levels (p=0.03) were significantly 
higher in patients with low CD4 counts than in patients with higher counts. Each of 
these inflammatory markers was correlated with the others (r: 0.18 to 0.39, 
p<0.0001 to 0.04), except IL-6 which did not correlate with sTNFR2. 
We thus wondered if the association between increased insulin resistance and low 
CD4 counts might be related to HIV-induced inflammation or active infection. We 
found no significant correlation between markers of inflammation and markers of 
insulin resistance. When the analysis was restricted to patients with hsCRP levels 
below 10 mg/L or to patients without clinical AIDS, T0 and T120 insulin and HOMA-
IR remained negatively correlated with CD4 counts, and still not with the tested 
inflammatory markers. 
 
In the final multiple linear regression model, higher age, higher BMI and low CD4 
counts were independently associated with increased insulin resistance, as 
represented by HOMA-IR (Table 4). The same relationships were observed when 
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considering other markers of insulin resistance such as T0 or T120 insulin, or when 
the analysis was restricted to patients without AIDS. Further adjustment for hsCRP, 
leptin and adiponectin, and triglycerides did not modify these results.  
In addition, in multiple regression analysis, when patients with #100 CD4/mm3 
(n=18) were differentiated from patients with 101-200 CD4/mm3 (n=24), we found 
that HOMA-IR was increased by +1.41 (p=0.0003) in patients with #100 CD4/mm3 
and by +0.82 (p=0.03) in patients with 101 to 200 CD4, compared with patients 
with more than 500 CD4/mm3. Although the pair-wise analysis did not evidence a 
significant difference between patients with #100 CD4/mm3 and patients with 101-
200 CD4/mm3, this result confirmed that patients with low or very low CD4 count 
are at increased risk of insulin resistance.  
In order to compare the effect-sizes of the three independent predictors of insulin 
resistance observed in this study, i.e. increased age, increased BMI, and low CD4 
count, we categorized age and BMI into four classes (#31, ]31-37], ]37-41] and 
>41 years old, and #19, ]19-25], ]25-30] and >30 kg/m2, respectively), with #31 
years old and ]19-25] kg/m2 as references. Patients aged ]31-37], ]37-41] and 
>41 years had an increased HOMA-IR by +0.19, +0.11 and +0.81, respectively, 
whereas patients with BMI of [25-30[ and >30 kg/m2 had an increased HOMA-IR by 
+0.48 and +0.76, respectively. Therefore, the effect-size of CD4 count below 200 
CD4/mm3 was higher (+1.11, Table 4) than that of the two other independent 
predictors of insulin resistance.  
 
Discussion  
The ANRS COPANA cohort of 800 patients living in France, with a recent diagnosis 
of HIV-1 infection and no antiretroviral exposure, is designed to examine 
relationships between HIV infection and subsequent metabolic disorders. In the 214 
patients enrolled in the metabolic sub-study, we evaluated insulin resistance and 
inflammatory markers, adipokines, and body fat amount and distribution. Our most 
striking finding is the correlation between immune deficiency and decreased insulin 
sensitivity in ART-naïve patients, independently of the amount and distribution of 
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body fat, and of systemic inflammation markers.  
Many studies have shown that insulin resistance is increased in ART-treated HIV-
infected patients and plays an important role in the pathogenesis of diabetes 
(reviewed in [8, 17]). Risk factors for altered insulin sensitivity are those found in 
the general population (increased BMI, visceral fat or age), but also factors linked 
to ART, lipodystrophy, or HIV/HCV co-infection. Low current or nadir CD4 count has 
also been associated with an increased risk of insulin resistance [23] or diabetes [3, 
5, 14, 15] in ART-treated patients, suggesting that HIV infection itself could 
modulate insulin sensitivity. However, confounding factors, including use of more 
diabetogenic ART in more severely affected patients, or disordered T-cells cytokine 
expression due to immune activation or reconstitution leading to increased 
inflammatory markers could not be excluded [3, 23]. Indeed, a subclinical 
inflammatory state has been shown to increase the risk of type 2 diabetes in the 
general population [24]. Therefore, searching for relationships between HIV-related 
factors, including inflammatory markers, and insulin sensitivity in ART-naïve 
patients is of important pathophysiological interest.  
Only two papers, both analysing data from the metabolic sub-study of the 
Community Program for Clinical Research on AIDS in the United States, have 
described the effects of HIV disease, before ART, on insulin sensitivity and glucose 
homeostasis [18, 19], one of them specifically studying the role of HCV co-infection 
[19]. An association between low CD4 counts and altered insulin sensitivity in ART-
naïve patients was found, but relationships with inflammatory markers and body fat 
amount and distribution have not been evaluated [18]. HOMA-IR was higher in this 
study than in our report (mean 2.2 ± 2.2 versus 1.5 ± 1.5) which could be 
explained by different characteristics of the patients, including a more severe state 
of immune deficiency, a higher prevalence of HCV infection [19] and of previous 
opiate use and a slightly higher BMI.  
In addition, we show here that the association between immune deficiency and 
altered insulin sensitivity was not related to a change in the amount or distribution 
of body fat, or to the studied inflammatory markers (hsCRP, IL-6, MCP-1, TNF", 
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sTNFR1 and sTNFR2). Indeed, although increased BMI is a well-known risk factor 
for insulin resistance, patients with CD4!200/mm3 were leaner than the other 
patients. In addition, their body fat was not differently distributed, and their 
SAT/TAT and SAT/VAT ratios were similar to those observed elsewhere in HIV-
uninfected individuals [25, 26]. Moreover, after adjustment for age, sex, BMI, waist 
circumference and geographic origin, all of which can modulate insulin sensitivity, 
we still found a correlation between insulin resistance markers (T0 and T120 
insulin, and HOMA-IR) and low CD4 counts, whereas HIV RNA load only correlated 
with T0 insulin. We also assessed inflammatory markers and serum adipokines, the 
latter being known to modulate insulin sensitivity both in the general population 
and in HIV-infected lipodystrophic patients [27, 28]. As expected, leptin correlated 
positively and adiponectin negatively with fasting insulinemia in our patients, who 
were not lipodystrophic, while immune deficiency was associated with systemic 
inflammation. However, we found no relationship between markers of insulin 
resistance and of inflammation in this cohort, even when the analyses were 
restricted to patients with only low-grade inflammation or without clinical AIDS. 
This result is important, since the occurrence of opportunistic or intermittent 
infections, in the context of immune deficiency, could induce metabolic changes. 
However, interestingly, in the early 1990s, before the multitherapy era, ten 
patients with AIDS did not present severe insulin resistance [29]. Opiate use and 
HCV infection have been associated with insulin resistance and/or diabetes in HIV-
infected patients [30], but these risk factors were uncommon in this cohort, and 
not overrepresented in the group of patients with low CD4 counts. Multivariate 
linear regression analysis showed that increased insulin resistance was 
independently related to increased age and BMI, as expected, but also to a low CD4 
count, which effect-size was higher than that of age >41 years or BMI >30 kg/m2. 
Adjustment for hsCRP, leptin, adiponectin and triglycerides did not modify these 
results. 
In these patients, with a median age of 36 years and a median BMI of 22.8 kg/m2, 
the prevalence of diabetes was 3.4% (without considering T120 glucose), a 
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frequency similar to that previously reported in HIV-infected antiretroviral-naïve 
patients when using the same definition [18, 19, 31]. We found that HOMA-B, a 
marker of insulin secretion, was significantly elevated in patients with low CD4 
counts. This may explain why fasting glycemia was normal, with increased insulin 
secretion compensating for increased insulin resistance. However, the post-charge 
T120 glycemia was increased, and when considering both fasting and post-charge 
glycemia, the prevalence of impaired glucose tolerance or diabetes tended to be 
increased in patients with low CD4 counts. These results, which suggest that insulin 
resistance associated with immune deficiency could lead to glucose tolerance 
abnormalities, have to be confirmed in larger groups.  
In the D.A.D study, patients of African origin had a 1.85 relative risk of developing 
diabetes during ART relative to Caucasians, probably owing partly to their higher 
BMI [6]. In contrast, El Sadr et al [18] reported that African Americans were more 
insulin sensitive than other HIV-infected ART-naïve patients possibly due to their 
lower BMI. In our study, we found an association or a trend for an association 
between sub-Saharan origin and altered insulin sensitivity, but not with impaired 
glucose tolerance and/or diabetes. However, after adjustement for geographic 
origin, low CD4 counts remained associated with altered insulin sensitivity. 
 
Our results have to be analyzed in the light of those recently reported by Brown et 
al. [16], showing that both low CD4 counts before ART and systemic low-grade 
inflammation after ART initiation, but not before ART, are risk factors for incident 
diabetes in ART-treated patients. Insulin resistance markers were not assessed in 
their study, but our data, together with their results, strongly suggest that low CD4 
count before ART initiation could be the first specific risk factor for altered insulin 
sensitivity and altered glucose tolerance linked to HIV infection. Then, chronic low-
grade inflammation after ART initiation could become another risk factor for insulin 
resistance and/or insulin secretion defects, leading to an increased risk of diabetes. 
Several studies, including those of large cohorts, have shown that low current or 
nadir CD4 count is an independent risk factor for atherosclerosis and cardiovascular 
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disease events [4, 9, 32], with inflammatory responses to HIV infection being 
thought to play a prominent role. Early altered insulin sensitivity, linked to immune 
deficiency before ART, could contribute to increased cardiovascular risk. 
 
Our results also suggest that several metabolic markers deteriorate as immune 
deficiency progresses. In particular, total, HDL- and LDL-cholesterol levels were 
lower and triglyceride levels higher in patients with low CD4 counts or high HIV 
RNA levels. Such changes in circulating lipids have already been linked to HIV 
infection [33] and replication [18]. Before the advent of effective antiretroviral 
therapy, wasting and cachexia associated with HIV infection were thought to play 
an important role in these abnormalities [34]. El Sadr et al. previously reported a 
correlation between BMI and serum lipid concentrations in antiretroviral-naïve 
patients [18]. In our study, including patients with less advanced immune 
deficiency and recent HIV diagnosis, only total and LDL-cholesterol correlated with 
BMI, and remained significantly associated with the CD4 count and HIV RNA load 
after adjustment for BMI. Therefore, immune deficiency and/or HIV replication are 
independently associated with altered serum lipid levels. Triglyceride levels also 
correlated with markers of insulin resistance and inflammation in our patients, but 
their relation with CD4 count persisted after adjustment for these markers. 
Inflammation has already been shown to increase the secretion of very-low-density 
lipoprotein-triglycerides [35], and a correlation between serum interferon-alpha and 
triglycerides levels has been described in HIV-infected subjects, before the use of 
highly active ART [36]. In addition, HIV infection has been linked to increased 
hepatic de novo lipogenesis [37, 38]. Our results suggest that immune deficiency 
tend to lower cholesterol and increase triglyceride levels, independently of the 
inflammatory markers tested. 
 
Our study has some limitations. The number of patients with CD4 below 200/mm3 
was relatively small, and the mean level of insulin resistance was mild: larger 
confirmatory studies are needed to estimate more precisely the relations between 
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immune deficiency, inflammatory and insulin resistance markers. However, we 
have studied several metabolic markers, assessed body fat distribution in more 
than one hundred patients, investigated with CT-scan and DEXA, and have 
measured a panel of six inflammatory markers. In addition, at the 
pathophysiological level, we have not demonstrated that immune deficiency has a 
direct role in promoting insulin resistance. Low CD4 level could be a marker for 
other abnormalities. Other potential factors, in particular immune activation and/or 
intestinal bacterial translocation, or vitamin D deficiency, which could be linked to 
insulin resistance, have not been studied here. Importantly, a low level of vitamin D 
has been recently reported to be associated with prevalent diabetes in a cohort of 
HIV-infected patients, most of them being ART-treated [39]. It would be interesting 
to study this factor in ART-naïve patients. 
 
In conclusion, this study shows that recently diagnosed HIV-infected antiretroviral-
naïve patients with low CD4 counts are susceptible to develop insulin resistance. 
Further studies are required to study the possible mechanisms linking low CD4 
counts to increased insulin resistance and also to determine whether insulin 
resistance, or mechanisms leading to insulin resistance, might aggravate HIV-
related immune deficiency. 
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Table 1: Baseline characteristics of the HIV-infected patients included in the metabolic sub-study of the ANRS COPANA cohort according to 
their CD4 counts. 
CD4 counts at baseline (/mm3) <200 
N=42 
]200-350] 
N=43 
]350-500] 
N=60 
> 500 
N=69 
p 
Characteristics 
Female sex  
 
Age (years) 
 
Geographic origin (N, %) 
 Europe 
 Sub-Saharan Africa 
 Others 
 
HIV-1 RNA levels (log10 copies/mL) 
 
Clinical AIDS (N, %) 
 
BMI (kg/m2) 
 
Waist circumference (cm) (n=205) 
 
Systolic blood pressure (mmHg) 
 
Diastolic blood pressure (mmHg) 
 
Fasting glucose (mmol/L) (n=202) 
 
Impaired glucose tolerance (n=175) 
 
Diabetes diagnosed with/without 
considering T120 glucose (N, %) 
(n=204/204) 
 
Impaired glucose tolerance or diabetes as 
diagnosed by T0 and T120 glucose (N, %) 
 
Total Cholesterol (mmol/L) (n=204) 
 
HDL-Cholesterol (mmol/L) (n=198) 
 
HDL-Cholesterol < 1 mmol/L (n=198) 
 
LDL-Cholesterol (mmol/L) (n=198) 
 
Triglycerides (mmol/L) (n=200) 
 
Triglycerides > 1.7 mmol/L (n=200) 
 
10 year-coronary heart disease 
risk>4%** (N,%) (n=214) 
 
Metabolic syndrome (21) (N,%) (n=214)  
17 (40.5) 
 
38 [33-47] 
 
 
12 (28.6) 
24 (57.1) 
6 (14.3) 
 
5.0 [4.4-5.5] 
 
21 (50.0) 
 
22.0 [20.3-24.2] 
 
80 [75-86] 
 
118 [110-128] 
 
70 [66-80] 
 
4.6 [4.2-4.9] 
 
2 (5.9) 
 
3/2 (7.7/5.1) 
 
 
 
5 (12.8) 
 
 
3.9 [3.4-4.8] 
 
1.0 [0.9-1.3] 
 
26 (65.0) 
 
2.3 [1.8-3.0] 
 
1.3 [0.9-2.1] 
 
16 (40.0) 
 
5 (11.9) 
 
 
5 (11.9) 
16 (37.2) 
 
37 [32-42] 
 
 
12 (27.8) 
21 (48.8) 
10 (23.3) 
 
4.3 [3.7-4.8] 
 
2 (4.7) 
 
22.9 [20.6-26.6] 
 
84 [73-92] 
 
120 [110-130] 
 
70 [67-78] 
 
4.9 [4.4-5.2] 
 
1 (3.1) 
 
3/3 (7.9/7.9) 
 
 
 
4 (10.5) 
 
 
4.0 [3.6-4.6] 
 
1.2 [0.9-1.5] 
 
18 (50.0) 
 
2.5 [2.0-3.0] 
 
0.9 [0.7-1.3] 
 
6 (16.2) 
 
3 (7.0) 
 
 
5 (11.6) 
11 (18.3) 
 
37 [31-44] 
 
 
39 (65.0) 
12 (20.0) 
9 (15.0) 
 
4.5 [4.0-4.9] 
 
0 (0.0) 
 
23.6 [21.3-26.1] 
 
86 [79-94] 
 
120 [110-139] 
 
70 [64-80] 
 
4.9 [4.4-5.3] 
 
1 (1.9) 
 
2/0 (3.4/0.0) 
 
 
 
3 (5.1) 
 
 
4.3 [3.8-4.9] 
 
1.1 [0.9-1.3] 
 
27 (46.6) 
 
2.8 [2.3-3.1] 
 
1.0 [0.6-1.3] 
 
10 (17.2) 
 
12 (20.0) 
 
 
10 (16.7) 
16 (23.2) 
 
33 [28-40] 
 
 
39 (56.5) 
18 (26.1) 
12 (17.4) 
 
3.9 [3.0-4.0] 
 
3 (2.9) 
 
22.5 [20.4-25.0] 
 
81 [75-89] 
 
120 [110-130] 
 
70 [64-75] 
 
4.7 [4.3-5.2] 
 
0 (0) 
 
2/2 (2.9/2.9) 
 
 
 
2 (2.9) 
 
 
4.5 [3.8-5.3] 
 
1.2 [1.0-1.4] 
 
20 (30.8) 
 
2.8 [2.3-3.5] 
 
0.9 [0.6-1.2] 
 
5 (7.6) 
 
11 (15.9) 
 
 
7 (10.1) 
0.04 
 
<0.001 
 
 
 
<0.001 
 
 
<0.001 
 
<0.001 
 
0.09* 
 
0.08* 
 
0.14* 
 
0.23* 
 
0.70* 
 
0.06* 
 
0.4/0.01* 
 
 
 
0.07* 
 
 
0.06* 
 
0.005* 
 
<0.001* 
 
0.008* 
 
<0.001* 
 
<0.001* 
 
0.29 
 
 
0.72 
 
Data are medians and 25th to 75th percentiles [IQR], or frequencies (%). * p values adjusted for sex. ** Framingham score.
Immune deficiency and insulin resistance in untreated HIV infection 
  
P
A
Table 2: Glycemia, insulin resistance markers, body fat distribution and adipokine levels according to the baseline CD4 counts in the HIV-infected patients 
included in the metabolic sub-study of the ANRS COPANA cohort. 
CD4 counts at baseline (/mm3) <200 
N=42 
]200-350] 
N=43 
]350-500] 
N=60 
> 500 
N=69 
p 
 
Markers 
T0 Glucose (mmol/L)  
 
T120 Glucose (mmol/L) 
 
T0 Insulin (mU/L) 
 
T120 Insulin (mU/L) 
 
HOMA-IR (n=202) 
 
SAT (cm2) (n=139) 
 
VAT (cm2) (n=139) 
 
SAT/VAT (n=139) 
 
% total body fat (n=102) 
 
% trunk fat (n=102) 
 
% limb fat (n=102) 
 
HOMA-B (n=200) 
 
Leptin (ug/L) 
 
Adiponectin (mg/L) 
 
4.6 [4.2-4.9] 
 
5.3 [4.2-6.8] 
 
6.6 [4.8-11.0] 
 
33.3 [18.7-53.6] 
 
1.4 [1.1-2.6] 
 
111.0 [44.2-160.8] 
 
63.2 [38.0-87.5] 
 
1.57 [1.06-2.17] 
 
16.0 [9.5-33.7] 
 
18.1 [8.8-35.7] 
 
13.1 [8.3-31.9] 
 
115.2 [76.0-173.1] 
 
2.7 [1.2-10.9] 
 
14.5 [11.3-16.8] 
 
4.9 [4.4-5.2] 
 
5.0 [4.6-5.7] 
 
5.8 [4.1-8.0] 
 
17.5 [7.8-25.2] 
 
1.3 [0.8-1.7] 
 
136.1 [98.7-213.3] 
 
70.5 [48.5-103.3] 
 
1.68 [1.26-3.35] 
 
24.9 [15.3-37.1] 
 
24.1 [12.2-36.3] 
 
19.0 [12.6-38.8] 
 
95.1 [45.4-133.3] 
 
4.6 [1.5-14.1] 
 
15.4 [9.0-17.9] 
 
4.9 [4.4-5.3] 
 
5.1 [4.2-5.3] 
 
4.8 [3.7-8.5] 
 
16.6 [6.7-37.6] 
 
1.1 [0.8-1.7] 
 
158.8 [74.4-200.5] 
 
84.2 [46.2-130.3] 
 
1.52 [1.16-2.18] 
 
20.9 [14.4-28.5] 
 
22.4 [11.6-30.9] 
 
18.9 [13.2-25.1] 
 
84.4 [52.9-117.5] 
 
5.3 [2.2-9.4] 
 
12.7 [9.2-16.4] 
 
4.7 [4.3-5.2] 
 
4.9 [4.2-5.6] 
 
4.8 [3.4-7.0] 
 
13.8 [9.0-24.0] 
 
1.0 [0.7-1.6] 
 
128.9 [84.6-190.9] 
 
60.5 [43.4-99.0] 
 
1.92 [1.33-3.86] 
 
22.3 [10.0-38.4] 
 
24.7 [12.2-38.9] 
 
19.3 [7.9-39.9] 
 
94.3 [59.2-125.0] 
 
3.1 [0.7-12.2] 
 
14.9 [9.0-17.9] 
 
0.70 
 
0.17 
 
0.02 
 
<0.001 
 
0.004 
 
0.29 
 
0.31 
 
0.28 
 
0.61 
 
0.59 
 
0.60 
 
0.02 
 
0.15 
 
0.58 
 
 
Data are medians and 25th to 75th percentiles [IQR], or frequencies (%). p values are adjusted for sex. SAT: subcutaneous adipose tissue; VAT: visceral adipose 
tissue, were assessed by L4 CT scans in 139 patients. % of total, trunk and limb fat were assessed by DEXA in 102 patients. 
Immune deficiency and insulin resistance in untreated HIV infection 
  
P
A
Table 3: Inflammatory markers according to the baseline CD4 counts in the HIV-infected patients enrolled in the metabolic sub-study of the ANRS COPANA 
cohort. 
 
CD4 counts at baseline (/mm3) <200 
N=42 
]200-350] 
N=43 
]350-500] 
N=60 
> 500 
N=69 
p 
 
Markers 
hsCRP (mg/L) 
 
MCP-1 (ng/L) 
 
TNF! (ng/L) 
 
sTNFR1 (ug/L) 
 
sTNFR2 (ug/L) 
 
IL-6 (ng/L) 
2.5 [0.6-8.2] 
 
210.8 [160.9-359.4] 
 
8.2 [6.6-12.7] 
 
2.1 [1.5-2.9] 
 
3.2 [2.2 –4.1] 
 
4.5 [2.1-9.5] 
1.2 [0.5-2.4] 
 
183.3 [112.6-308.6] 
 
5.6 [4.0-8.7] 
 
1.7 [1.4-2.1] 
 
2.7 [2.2-3.1] 
 
2.2 [1.2-3.7] 
1.1 [0.6-2.1] 
 
262.3 [158.7-347.8] 
 
7.3 [4.8-9.5] 
 
1.7 [1.2-1.9] 
 
2.5 [2.0 –3.2] 
 
2.9 [1.0-4.0] 
1.2 [0.6-3.7] 
 
181.3 [126.8-325.0] 
 
5.0 [3.7-7.3] 
 
1.6 [1.2-2.0] 
 
2.6 [1.6 –2.9] 
 
2.1 [0.8-4.6] 
0.15 
 
0.14 
 
<0.001 
 
0.03 
 
0.008 
 
0.007 
 
 
Data are medians and 25th to 75th percentiles [IQR], or frequencies (%). Significance was determined with the Kruskal-Wallis test. 
Immune deficiency and insulin resistance in untreated HIV infection 
  
P
A
Table 4: Univariate and multivariate linear regression analysis of the role of age, sex, BMI, geographic origin, and the CD4 counts 
or HIV-1 RNA levels in insulin resistance (HOMA-IR) in the HIV-infected patients included in the metabolic sub-study of the ANRS 
COPANA cohort. The multivariate analysis included either the CD4 count or the HIV viral load (see Methods). 
 
 
 
Univariate 
 
Multivariate 
Characteristics 
beta 
coefficient 
 
p value 
beta 
coefficient  
 
p value 
beta 
coefficient 
 
p value 
 
Age* 
 
+0.34 
 
0.003 
 
+0.26 
 
0.01 
 
+0.34 
 
0.001 
 
Female sex 
 
+0.45 
 
0.06 
 
+0.04 
 
0.88 
 
+0.14 
 
0.55 
 
BMI** 
 
+0.07 
 
0.002 +0.07 0.003 +0.05 0.02 
 
Geographic origin 
 
+0.42 
 
0.06 -0.12 0.59 +0.03 0.89 
 
CD4 count (/mm3) 
>500 
]350-500] 
]200-350] 
!200 
 
 
Reference 
+0.09 
+0.11 
+1.11 
 
 
 
0.72 
0.71 
0.0002 
 
 
Reference 
+0.07 
+0.11 
+0.90 
 
 
 
0.76 
0.67 
0.001 
  
 
HIV-RNA (log copies/mL) 
!3.70 
]3.70-4.35] 
]4.35-4.86] 
>4.86 
 
 
Reference 
-0.02 
-0.21 
-0.23 
 
 
 
0.95 
0.48 
0.44 
   
 
Reference 
+0.41 
+0.16 
+0.18 
 
 
 
0.11 
0.54 
0.48 
 
* per a 10-year increase; ** per a 1-kg/m2 increase.  
Females were compared to males, and patients of Sub-Saharan Africa origin to other patients.  
HIV-RNA levels were categorized according to the 25th, 50th, and 75th percentiles.
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